Journal Article

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement

Geng, Hongzhi, Zeng, Liangyu, Li, Caixia, Li, Jiaqi, Wu, Depei, Yang, Qin, Lu, Yutong, Zhou, Jin, Zhang, Ying, Jia, Sixun, Lu, Shuangzhu, Zong, Xiangping

2023

Overview

IntroductionTreatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows poor response rates in non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) patients with multiple extranodal involvement. This study aims to evaluate anti-tumor activity and safety of zanubrutinib with R-CHOP (ZR-CHOP) in treatment naïve non-GCB DLBCL with extranodal involvement.MethodsIn this single-arm, phase 2, prospective, single-center study, patients with newly diagnosed non-GCB DLBCL with extranodal involvement enrolled between October 2020 to March 2022 received ZR-CHOP for 6 cycles followed by 2 cycles of maintenance treatment with rituximab and zanubrutinib. The primary endpoint included progression-free survival (PFS) in the intent-to-treat (ITT) population whereas the secondary endpoints included overall response rate (ORR), complete response (CR), and duration of response. Further, next-generation sequencing (NGS) was used for detection of different oncogenic mutations closely related to DLBCL pathogenesis.ResultsFrom October 2020 to March 2022, 26 patients were enrolled, and 23 of them were evaluated for efficacy after receiving 3 cycles of ZR-CHOP treatment. 1-year PFS and OS were 80.8% and 88.5% respectively while expected PFS and OS for 2-years are 74.0% and 88.5% respectively with median follow-up of 16.7 months and ORR was 91.3% (CR: 82.61%; PR: 8.70%). Oncogenic mutations closely related to DLBCL pathogenesis were assessed in 20 patients using NGS. B-cell receptor and NF-κB pathway gene mutations were detected in 10 patients, which occurred in MYD88 (7/19), CD79B (4/19), CARD11 (5/19), and TNFAIP3 (2/19). Hematological adverse events (AEs) ≥ grade 3 included neutropenia (50%), thrombocytopenia (23.1%), and anemia (7.7%) whereas non-hematological AEs ≥ grade 3 included pulmonary infection (19.2%).ConclusionZR-CHOP is safe and effective for treating treatment naïve non-GCB DLBCL patients with extranodal involvement.Clinical Trial RegistrationClinicaltrials.gov, NCT04835870

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: anti-tumor activity / Antitumor agents / B-cell lymphoma / B-cell receptor / Clinical trials / Cyclophosphamide / Doxorubicin / extranodal involvement / Germinal centers / Hepatitis B / Immunohistochemistry / Immunology / Kinases / Lymphocytes B / Lymphoma / Medical prognosis / Mutation / MyD88 protein / Neutropenia / Neutrophils / Next-generation sequencing / NF-κB protein / oncogenic mutations / Pathogenesis / Patients / Performance evaluation / Point mutation / Prednisone / Remission (Medicine) / Rituximab / Skin cancer / Thrombocytopenia / Tomography / Tumors / untreated non-GCB DLBCL / Vincristine / zanubrutinib